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Abstract 
Background 
The insulin-sensitizing phytocannabinoid, Δ(9)-tetrahydrocannabivarin (THCV) can signal partly via 
G-protein coupled receptor-55 (GPR55 behaving as either an agonist or an antagonist depending on 
the assay). The cannabinoid receptor type 1 (CB1R) inverse agonist rimonabant is also a GPR55 
agonist under some conditions. Previous studies have shown varied effects of deletion of GPR55 on 
energy balance and glucose homeostasis in mice. The contribution of signalling via GPR55 to the 
metabolic effects of THCV and rimonabant has been little studied. 
Methods 
In a preliminary experiment, energy balance and glucose homeostasis were studied in GPR55 knockout 
and wild-type mice fed on both standard chow (to 20 weeks of age) and high fat diets (from 6 to 15 
weeks of age). In the main experiment, all mice were fed on the high fat diet (from 6 to 14 weeks of 
age). In addition to replicating the preliminary experiment, the effects of once daily administration of 
THCV (15 mg.kg-1 po) and rimonabant (10 mg.kg-1 po) were compared in the two genotypes. 
Results 
There was no effect of genotype on absolute body weight or weight gain, body composition measured 
by either dual-energy X-ray absorptiometry or Nuclear Magnetic Resonance (NMR), fat pad weights, 
food intake, energy expenditure, locomotor activity, glucose tolerance or insulin tolerance in mice fed 
on chow. When the mice were fed a high fat diet, there was again no effect of genotype on these various 
aspects of energy balance. However, in both experiments, glucose tolerance was worse in the knockout 
than the wild-type mice. Genotype did not affect insulin tolerance in either experiment. Weight loss in 
rimonabant- and THCV-treated mice was lower in knockout than in wild-type mice, but surprisingly there 
was no detectable effect of genotype on the effects of the drugs on any aspect of glucose homeostasis 
after taking into account the effect of genotype in vehicle-treated mice. 
Conclusions 
Our two experiments differ from those reported by others in finding impaired glucose tolerance in 
GPR55 knockout mice in the absence of any effect on body weight, body composition, locomotor activity 
or energy expenditure. Nor could we detect any effect of genotype on insulin tolerance, so the possibility 
that GPR55 regulates glucose-stimulated insulin secretion merits further investigation. By contrast with 
the genotype effect in untreated mice, we found that THCV and rimonabant reduced weight gain, and 
this effect was in part mediated by GPR55. 
  
Introduction 
Previous work from our laboratory has shown that the plant-derived cannabinoid, Δ(9)-
tetrahydrocannabivarin (THCV) improves insulin sensitivity in diet-induced obese and ob/ob mice 
(Wargent et al., 2013) but it is not clear which receptor or receptors mediate its effects.  Cannabinoids, 
signal partly via GPR55 (Pertwee, 2007; Sharir and Abood, 2010). THCV was a high efficacy, low affinity 
agonist of ERK1/2 phosphorylation when hGPR55 was expressed in HEK293 cells but it inhibited L-α-
lysophosphatidylinositol  signalling (Anavi-Goffer et al., 2012). The cannabinoid receptor type 1 (CB1R) 
inverse agonist rimonabant, which was in the past used for the treatment of obesity, is also a GPR55 
agonist (Kapur et al., 2009; Henstridge et al., 2010), although under some conditions it can behave as 
an antagonist (Lauckner et al., 2008; Anavi-Goffer et al., 2012).  
There is conflicting evidence as to whether GPR55 agonists or antagonists might be of benefit in the 
treatment of obesity or type 2 diabetes (Lipina et al., 2012; Moreno-Navarrete et al., 2012; Henstridge 
et al., 2016). Some findings in humans suggest that GPR55 receptor antagonists should reduce food 
intake and body weight (Henstridge et al., 2016). By contrast, in support of GPR55 agonists, two studies 
found that GPR55 knockout mice showed increased adiposity and insulin resistance associated with 
decreased locomotor activity (Meadows et al., 2016, Lipina et al., 2019), although another failed to 
demonstrate increased adiposity and locomotor activity was actually increased during the first six hours 
of the dark period (Bjursell et al., 2016). Further support for the potential of GPR55 agonists in the 
treatment of type 2 diabetes comes from two studies that have found that the GPR55 agonist O-1602 
stimulated insulin secretion from wild-type but not GPR55 -/- murine islets of Langerhans (Romero-
Zerbo et al., 2011; Liu et al., 2016). In one of these studies (Romero-Zerbo et al., 2011), it was also 
shown that O-1602 stimulated insulin secretion and improved glucose tolerance in vivo in rats. 
Previous studies in GPR55 knockout mice have mostly been conducted using mice fed on a standard 
chow diet. Here we first compared GPR55 knockout and wild-type mice fed on both standard chow and 
high fat diets. We found that oral glucose tolerance was worse in GPR55 knockout than in wild-type 
mice when the mice were fed on a high fat diet but not when they are fed on a chow diet. To investigate 
the role of GPR55 in responses to THCV and rimonabant, we therefore compared metabolic responses 
to these drugs in wild type and GPR55 knockout mice fed on a high fat diet. We report that THCV and 
especially rimonabant had less effect on body weight gain in GPR55 knockout than in wild-type mice 
but we were unable to demonstrate genotype influenced changes in glucose homeostasis in response 
to THCV or rimonabant. 
Materials and Methods 
Mice 
Two male and five female GPR55+/- mice on a C57Bl/6 background were kindly supplied, with the 
permission of AstraZeneca, Macclesfield, UK, by Professor Cherry Wainwright of the Institute for Health 
and Welfare Research, The Robert Gordon University Aberdeen AB10 1FR, UK. They were bred to 
produce GPR55-/- (‘knockout’) and wild-type mice. The final breeding-round for the current studies was 
between homozygous wild-type or knockout mice.  
In the preliminary experiment, the purpose of which was solely to compare the phenotypes of wild-type 
and GPR55 knockout mice, the intention was to use 12 wild-type and 12 knockout male mice in each 
experiment (chow-fed or high fat diet-fed), housed in pairs. Only 11 knockout mice were available for 
the high fat diet experiment, however. 
In the main experiment, which focussed on mice fed on a high fat diet and investigated whether 
responses to THCV (15 mg.kg-1 po once daily; GW Research Ltd, Cambridge, UK) and rimonabant (10 
mg.kg-1 po once daily) differed between genotypes, the intention was again to use 12 wild-type and 12 
knockout mice, housed in pairs, in each group. However, one mouse died before the experimental 
period began, one mouse died in each of the control groups, and one mouse died in the rimonabant 
wild-type group (tumour found in chest). All data for these mice have been excluded. The vehicle for 
both THCV and rimonabant was 2.5% ethanol in sesame seed oil (10 ml.kg-1)l. 
The mice were housed at 24-26C with lights on at 08:00 and off at 20:00. Mice were housed in pairs 
in the preliminary study and 3 per cage in the main study. They were fed at weaning on chow (Beekay 
rat and mouse diet No 1; BK001E; Beekay Feed, B&K Universal Limited) and from six weeks of age on 
a high fat diet (metabolizable energy: 60% fat; 20% carbohydrate; 20% protein; Research Diets, New 
Brunswick, NJ, USA; product #D12492). Food and water were provided ad libitum. Cages had solid 
bases with sawdust for foraging and digging. Cotton fibre nestlets and Enviro-Dri paper were provided 
as bedding and cover. Cardboard houses and tunnels were also provided for shelter, exploration, and 
gnawing. Wood chew sticks were also provided for gnawing. Interlocking PVC sections were used for 
climbing and compartmentalisation. 
All procedures involving animals were conducted in accordance with the University of Buckingham 
Animals (Scientific Procedures) Act 1986 (ASPA)  Ethical Review Board and theASPA Project Licence 
(PPL) licence number: 70/7164).). ARRIVE guidelines were followed in the reporting of the experiments. 
Mice were inspected daily for adverse effects and after every procedure. At the end of the study all mice 
were killed by concussion of the brain by striking the cranium followed by cervical dislocation.  
Criteria for euthanizing animals before the end of study were as follows. Any animal showing signs of 
mis-dosing or damage after oral gavage, such as by coughing/choking or collapsing after administration 
of substances will be killed by an approved method. Animals receiving intraperitoneal dosing will be 
observed immediately after dosing and if treatment is for a prolonged period, we will monitor the animals 
for signs of pain and distress that may indicate peritonitis (hunching, subdued behaviour, hind limb 
extension). Any animal showing signs of damage will be humanely killed. Following blood sampling 
animals showing lasting signs of damage or exceeding the mild severity limit will be humanely killed. In 
the insulin sensitivity tests any animal that shows signs of torpor after insulin administration will 
immediately be given glucose and/or glucagon by the intra-peritoneal route, monitored continuously 
and killed if it fails to respond to stimulation or does not recover within 20 minutes. None of these criteria 
was necessary to be implemented in the preliminary study. Four animals in the main study experienced 
distress due to oral mis-dosing and were culled by concussion followed by cervical dislocation. This 
incidence rate was within the expected maximum of less than 1 in a thousand doses set out in the terms 
of the project licence. 
Experimental Methods 
Energy expenditure was measured by open circuit indirect calorimetry with mice in their home cages 
(Arch et al., 2006).  
For the measurement of locomotor activity, mice were kept in the cages (28 x 12 cm) in which they 
normally housed. They remained in their pairs. Video camera shots were taken every hour for 10 min, 
beginning 1 hour before the dark period. Thus, the first recording was at 19:00 and the last at 08:00. 
The recordings were digitally divided by black lines into three equal rectangles after filming. Horizontal 
locomotor activity was assessed by one independent observer from the number of times a mouse 
crossed a line during those 10 minutes in a blinded study.  
Body fat and lean content was measured using a Minispec LF90II Nuclear Magnetic Resonance (Bruker 
Corporation, Germany). Dual-energy X-ray absorptiometry (DXA or DEXA) was also used in the 
preliminary experiment because it gives a measure of bone density, and it has been reported that bone 
structure is altered in GPR55 knockout mice (Whyte et al., 2009). 
Insulin tolerance was measured after mice had been fasted for five hours before being dosed with 
insulin (Actrapid™ (Centaur Services, UK) at 0.5 units/kg body weight, i.p. for chow-fed mice and 0.75 
units/kg bodyweight for high fat diet-fed mice). Blood samples for glucose measurement were taken 10  
min and immediately before, and 10, 20, 30 45 and 60 min after the administration of insulin. 
Pancreatic insulin concentration and content were measured at termination. The mice were fasted from 
09:00 and humanely killed at 14:00. Pancreatic insulin content (Wang et al. 2002), liver glycogen 
(Pearce et al. 2004), blood glucose and insulin, liver triglycerides and oral glucose and intraperitoneal 
insulin tolerance tests (Wargent et al. 2013) were conducted as described previously. 
 
Statistics 
Results given in the text, and data-points in the figures are shown as the mean  SEM. Sample size 
was calculated by the resource equation method (Festing and Altman, 2002). All data sets passed the 
Anderon-Darling test for normality of distribution (alpha of 0.05). The statistical significance of any 
differences between vehicle-treated animals and drug-treated animals was determined using Student’s 
t-test, or where there were multiple treatments or time-points, 1-way or 2-way ANOVA followed by False 
Discovery Rate post-tests (FDR; two-stage linear step-up procedure of Benjamini, Krieger and 
Yekutieli), using Prism 7. ROUT was used to analyse data sets for outliers with no outliers being 
identified. In the FDR test Q (adjusted P value) is the lowest value that gave ‘Yes’ in the Discovery 
column of the analysis. Statistical significance is shown as: *P or Q <0.05, **P or Q <0.01; ***P or Q 
<0.001; ****P or Q <0.0001.  
 
Results 
Preliminary experiment 
The mice were fed on chow and then some were fed on a high fat diet from 6 weeks of age.  
Weight gain was significantly greater (Q < 0.0001 for both wildtype and knockout mice) between 6 and 
11 weeks of age in mice fed on a high fat diet (wild type: 12.6 ± 0.9 g, n =12; knockout:12.2 ± 1.3 g, n 
= 11) than in mice fed on chow (wild type: 6.1 ± 0.4 g, n =12; knockout: 5.2 ± 0.4 g, n = 12). However, 
irrespective of diet, there was no statistically significant effect of genotype on absolute body weight or 
weight gain (Figure 1), body composition measured by either DXA or NMR, fat pad weights, food intake, 
energy expenditure or locomotor activity (Table 1 for chow-fed mice; Table 2 for high fat-fed mice); nor 
on the time courses of energy expenditure and locomotor activity (results not shown, but are in the 
supplementary data file). 
In the chow-fed mice, two-way ANOVA with time matching showed no effect of genotype on blood 
glucose in the glucose tolerance test (Figure 2A). There was no effect of genotype on plasma insulin at 
+30 or -30 min relative to the administration of glucose (Figure 2B). Insulin tolerance, whether 
expressed in terms of absolute blood glucose levels or the fall in blood glucose following injection of 
insulin, was no different between genotypes in the chow-fed mice at 20 weeks of age in either absolute 
blood glucose concentrations (Figure 2C) or in change in blood glucose (Figure 2D). 
By contrast with the chow-fed mice, there were clear effects of genotype on blood glucose and plasma 
insulin in the glucose tolerance test and on insulin tolerance in the mice fed on the high fat diet (Figure 
3). Thus, two-way ANOVA with time-matching followed by the FDR test showed that blood glucose was 
higher in the knockout than the wild-type mice 30 and 60 min after dosing with glucose (Q<0.01; Figure 
3A), and two-way ANOVA followed by the FDR test showed that plasma insulin was also higher in the 
knockout than the wild-type mice 30 min after administration of glucose (Q<0.01; Figure 3B).  
Blood glucose 20 to 60 min after administration of insulin in the insulin tolerance test was higher in the 
knockout mice (Q<0.01; Figure 3C). However, the fall in blood glucose following the injection of insulin 
was not significantly different between genotypes (Figure 3D).  
Liver weight, liver glycogen and lipid contents, pancreatic insulin concentration and pancreatic total 
insulin content were not affected by genotype irrespective of diet (results not shown, but are in the 
supplementary data file). 
Main experiment 
The effects of 15 mg.kg-1 po THCV and 10 mg.kg-1 po rimonabant were compared between wild-type 
and GPR55 knockout mice fed on the high fat diet.  
Confirmation of results of preliminary experiment 
It was confirmed (for mice fed on a high fat diet) that energy balance is no different between GPR55 
knockout and wild-type mice. The mean body weight of the vehicle-treated knockout mice was less than 
that of the vehicle-treated wild-type mice from the beginning of the study, but differences in body weight 
were not statistically significant at this or any other time. Analysis of body weight change showed higher 
increases in body weight for the knockout mice at 21, 28 and 35 days, but by 56 days the wild-type 
mice had the higher increase (Figure 4A) and there was no overall effect on genotype on body weight 
gain. As in the preliminary study, genotype had no effect on food intake (results not shown, but are in 
the supplementary data file), energy expenditure (Figure 5), body composition measurements (Figure 
6) or fat pad weights (Table 3).  
It was confirmed that glucose homeostasis is deficient in GPR55 knockout mice. As in the untreated 
mice in the preliminary study, blood glucose was higher in the vehicle-treated knockout than in the 
vehicle-treated wild-type mice 30 min (Q<0.01) and 60 min (Q<0.05) after giving glucose in the glucose 
tolerance test on day 21 (Figure 7A) and plasma insulin 30 min after giving glucose was higher in the 
vehicle-treated knockout mice than in the vehicle-treated wild-type mice (Q<0.05; Figure 8A).  
Although the same trend was seen as in the preliminary experiment, there was no significant difference 
in the insulin tolerance curves on day 38 between the vehicle-treated knockout mice and the vehicle-
treated wild-type mice (Figures 9A and 9B). As in the preliminary experiment, there was also no 
difference in the fall in blood glucose when the data were normalised to the 0 min blood glucose values 
(Figures 9C and 9D) or the -10 min values (data not shown, but are in the supplementary data file). 
Responses to THCV and rimonabant: energy balance 
Two-way ANOVA with time-matching showed an overall effect of genotype on body weight gain in 
response to both THCV (P < 0.001; Figure 4B) and rimonabant (P < 0.001; Figure 4C) from day 8 due 
to both THCV and rimonabant being less effective in the knockout mice. Although the effect of genotype 
on body weight gain in THCV-treated mice was statistically significant on days prior to day 56 and over 
all days, it was not statistically significant for THCV on the final day (day 56), being only 19% less in 
knockout than in wild-type mice (6.7 g different from control in wild-type mice; 5.5 g different from 
controls in knockout mice). By contrast, the effect of rimonabant on body weight gain on day 56 was 
significant, being 33% less in knockout than wild-type mice (10.2 g different from control in wild-type 
mice: 6.8 g different from controls in knockout mice). Two-way ANOVA (treatment; genotype) of the 
weight changes on day 56 did not show an interaction between the effects of genotype and treatment 
(P = 0.06), so it cannot be claimed that GPR55 contributed more to the effect of rimonabant on weight 
loss than to the effect of THCV. Nor, in the absence of pharmacokinetic and concentration-response 
data for effects of rimonabant and THCV on GPR55- and CB1R-mediated responses in mouse tissues 
(such as the hypothalamus) can we attempt to explain why rimonabant caused more weight loss than 
THCV. 
There was no effect of genotype or drug treatment on total food intake (results not shown, but are in 
the supplementary data file). Rimonabant raised energy expenditure significantly in the WT but not the 
KO mice on days 25 to 29, but there was not a statistically significant difference between its effects in 
WT and KO mice (Figure 5). 
Locomotor activity was measured on day 45 in the control and rimonabant-treated mice only. Neither 
genotype nor rimonabant had any effect on total locomotor activity or its time course (results not shown, 
but are in the supplementary data file). 
There was no effect of genotype or treatment on lean body mass or body fat content on day 32 (Figures 
6A, 6B). The failure to demonstrate an effect of genotype on terminal body fat content despite the effect 
on body weight gain being lower in knockout mice appears to be due to the initial mean body weights 
(and presumably body fat contents) of the knockout mice being (non-significantly) lower than those of 
the corresponding wild-type groups. Body fat content was less in animals treated with THCV or 
rimonabant than in the control group of the same genotype, but this was not reflected in significantly 
reduced epididymal, inguinal of interscapular fat fad weights (Table 3).  
Responses to THCV and rimonabant: glucose homeostasis 
There was no effect of genotype on blood glucose after a 5 h fast on days 8,15 and 56 (Figures 10A, 
10B and 10C). Blood glucose was lower in the THCV-treated wild-type mice on day 15 (Figure 10B) but 
not on days 8 or 56. At no time did rimonabant-treated wild-type mice or knockout mice treated with 
either THCV or rimonabant show reduced blood glucose (Figures 10A, 10B and 10C). 
There was also no effect of genotype on plasma insulin on days 8, 15 and 56 (Figures 10D, 10E and 
10F). On days 8 and 15 plasma insulin was lower in the THCV-treated and rimonabant-treated than in 
the control mice of the same genotype, although this only reached statistical significance in rimonabant-
treated knockout mice on day 8 and rimonabant-treated wild-type mice on day 15. After 56 days of 
dosing both THCV and rimonabant reduced fasting plasma insulin in wild-type mice, but neither THCV 
nor rimonabant altered plasma insulin concentrations in GPR55 knockout mice (Figure 10F). The effects 
of THCV and rimonabant on plasma insulin were not significantly different in wild-type or GPR55 
knockout mice at any time point (Figures 10G, 10H and 10I).   
An oral glucose test was conducted on day 21. THCV (P < 0.05) and rimonabant (P < 0.05) improved 
glucose tolerance in wild-type mice (P < 0.05, Figure 7B). Neither THCV nor rimonabant had an overall 
significant effect on OGTT in GPR55 knockout mice, although rimonabant did significantly lower blood 
glucose 30 min after glucose load (P < 0.01), Figure 7C). However, no genotype differences were 
observed in the relative effects of either THCV and rimonabant after accounting for the genotype effect 
on glucose tolerance in vehicle-treated mice (Figures 7D and 7E). 
THCV- and rimonabant-treated wild-type and knockout mice had lower plasma insulin concentration 30 
min before (Figure 8B) and 30 min after (Figure 8C) a glucose load, although this only reached statistical 
significance in wild-type mice, although two-way ANOVA showed no interaction between the effect of 
treatment and genotype. Expressing the insulin concentrations relative to the respective genotype 
control groups also showed no significant genotype differences in the effect of either THCV or 
rimonabant 30 min before (Figure 8D) or 30 min after glucose load Figure 8E). 
An insulin tolerance test was conducted on day 38. Blood glucose was lower in the THCV-treated wild-
type mice than in the control wild-type mice both before and after administration of insulin. There was 
a small overall effect of rimonabant (Figure 9A). However, there was no overall effect of either drug on 
the fall in blood glucose after giving insulin to WT mice (Figure 9C).  
The fall in blood glucose in the THCV-treated mice after giving insulin reached statistical significance in 
the knockout but not the THCV-treated mice (Figure 9). However, these falls did not differ significantly 
between the genotypes, there being no effect of genotype on the fall in blood glucose concentration 
with either THCV or rimonabant (see Figure 8D for absolute values). 
Discussion 
The present study addresses two broad questions: first, whether there are differences in energy balance 
and glucose homeostasis between wild-type and GPR55 knockout mice; second whether any effects 
of THCV or rimonabant differ between wild-type and GPR55 knockout mice. Our main findings are that 
impaired glucose tolerance in GPR55 knockout mice is restricted to mice fed on a high fat diet but is 
not associated with increased adiposity, and that when they are fed on a high fat diet, rimonabant and 
THCV have less effect on weight gain in GPR55 knockout than wild-type mice. We acknowledge that 
for logistical and ethical reasons, including the restriction of our UK Home Office licence, we could not 
conduct all measurements at the ideal time. We also acknowledge that ideally, we would have 
conducted our experiments in both male and female mice, but it was not logistically possible to do this. 
We chose to use male mice because Meadows et al (Meadows et al., 2016), Lipina et al, (Lipina et al., 
2019) and Bjursell et al (Bjursell et al, 2016) used male mice. If we had used female mice, any 
differences between our results and theirs could be ascribed to the use of different sexes.  Despite 
these limitations, we believe that our results have value. Other studies have the same limitations. 
Phenotypic differences between wild-type and GPR55 knockout mice 
There were no differences in any aspects of energy balance (body weight, body weight change, total 
food consumption, daily energy expenditure, locomotor activity or body composition) between the 
untreated (preliminary experiment) or vehicle-treated (main experiment) wild-type and knockout mice.  
Our findings differ from those of Meadows et al (Meadows et al., 2016) and Lipina et al, (Lipina et al., 
2019), despite our mice being kindly supplied by one of the authors of the latter study. Both groups 
studied GPR55 knockout mice fed on chow but not on a high fat diet. The chow-fed GPR55 knockout 
mice had a higher mean body weight and fat content than wild-type mice. (Meadows et al. state that 
there is a numerical difference in body weight but acknowledge that it is not statistically significant.)  
The weights of some fat pads were also higher in the knockout mice. Lipina et al. reported that there 
was a significant reduction in lean body mass but this was expressed as a percentage of body weight 
and the consequence of increased fat mass. Meadows et al. found that genotype had no effect on food 
intake or resting metabolic rate, but spontaneous locomotor activity was lower in the knockout than the 
wild-type mice during the dark period.  
Our results agree with those of Bjursell et al (Bjursell et al, 2016) in that that these investigators did not 
find increased body weight in the knockout mice, except for a non-significant increase in fat mass 
relative to body weight when the mice were fed on a ‘cafeteria-fed’ mice and aged 28 weeks. Our mice 
were killed at 15 weeks of age. These workers found increased locomotor activity in the knockout mice 
during the first 6 hours of the dark period although energy expenditure was not raised at this time. 
During the second 6 hours of the dark period, energy expenditure was no higher in their knockout than 
their wild-type mice and energy expenditure was depressed. We found no evidence that locomotor 
activity or energy expenditure was different in the knockout than the wild-type mice at any time during 
the dark period.  
By contrast with our negative findings on energy balance, we found differences in glucose homeostasis 
between the untreated (preliminary experiment) or vehicle-treated (main experiment) wild-type and 
knockout mice in both experiments when the mice were fed on a high fat diet. The preliminary 
experiment found at most minor differences when the mice were fed on chow.  
In both the preliminary and the main experiment, blood glucose was higher in knockout than in wild-
type high fat diet-fed, untreated/vehicle-treated mice 30 and 60 min after giving glucose in an oral 
glucose tolerance test. The overall blood glucose level was also higher in the knockout mice. In both 
experiments, plasma insulin 30 min after giving glucose was higher in the knockout than the wild-type 
high fat diet-fed mice. These results suggest that insulin sensitivity was impaired in the knockout mice. 
Insulin tolerance tests failed to back this up, however. The failure to demonstrate an effect of genotype 
on fasting blood glucose and plasma insulin in either the preliminary or the main experiment was also 
unsupportive of an effect of genotype on insulin resistance. We must therefore look beyond increased 
adiposity and consequent insulin resistance to account for impaired glucose tolerance in our GPR55 
knockout mice. 
It is feasible that impaired insulin secretion contributed to impaired glucose tolerance: plasma insulin 
was raised in the knockout mice after administration of glucose, but perhaps if it had been even higher 
glucose tolerance would have been normal. Others have reported that the GPR55 agonist O-1602 
stimulated insulin secretion from wild-type but not GPR55 -/- murine islets of Langerhans (Henstridge 
et al., 2016; Meadows et al., 2016) and Meadows also shows O-1602 stimulated insulin secretion and 
improved glucose tolerance in vivo in rats. If impaired insulin secretion is the explanation for our 
findings, then it seems to be exacerbated by the high fat diet. 
Other workers (Lipina et al., 2019) have reported that GPR55 knockout mice have impaired insulin 
sensitivity but this may be because their mice displayed increased adiposity. In fact, although they found 
that blood glucose fell significantly in wild-type but not knockout mice following administration of insulin, 
they did not find a significant difference between genotypes. They demonstrated more clearly significant 
differences between genotypes in insulin signalling in isolated liver, skeletal muscle and adipose 
tissues.  By contrast with our results, the chow-fed GPR55 knockout mice of Meadows et al. (Meadows 
et al., 2016) showed impaired insulin tolerance, but they did not exhibit impaired glucose tolerance. 
Meadows et al. point to raised basal insulin and a decreased response of insulin to glucose, but they 
did not show that these were statistically significant differences from wild-type mice. Bjursell et al 
(Bjursell et al., 2016), who like us did not find increased adiposity in GPR55 knockout mice, have not 
reported studies on glucose homeostasis. 
Some of the differences between our findings and those of Meadows et al (Meadows et al, 2016) may 
be due to their conducting glucose and insulin tolerance when their mice were nine months old, whereas 
our chow-fed mice in the preliminary study were 16- (glucose tolerance) or 20- (insulin tolerance) 
weeks-old. Their mice were therefore fatter and more like our high fat-fed mice. Lipina et al. conducted 
their measurements when the mice were 10-22 weeks old (Lipina et al, 2019). 
Thus, our results suggest that GPR55 interacts with insulin signalling in a more direct way than via 
increased fat mass. This mechanism merits further investigation. Despite many differences in details 
between the findings of those who have studied GPR55 knockout mice, including ourselves, we agree 
that GPR55 agonists might be of value in the treatment in type 2 diabetes. 
Effects of THCV and rimonabant 
The beneficial effects of rimonabant on energy balance and glucose homeostasis in HFD-fed wild-type 
mice are well-known (Arch, 2011). They were reproduced in the present study.  
We have previously described beneficial effects of THCV on blood glucose and plasma insulin in the 
fasting state and following an oral glucose load in high fat-fed obese mice (Wargent et al., 2013). Similar 
results were obtained in the present study in both wild-type and GPR55 knockout mice using a dose of 
THCV that was towards the top of the range used in the previous study. One notable difference between 
the studies, however, is that in the previous study (Wargent et al, 2013) THCV did not affect body weight 
(the same was true in ob/ob mice), whereas in the present study THCV reduced body weight, weight 
gain and body fat content in both the wild-type and knockout mice. This was achieved without any 
reduction in total food intake and neither did THCV elicit a significant increase in energy expenditure. 
However, there was a numerical increase in energy expenditure in the wild-type (but not the knockout) 
mice that did not reach statistical significance, and in increase an energy expenditure was detected in 
our previous study (Wargent et al, 2013). Energy expenditure was measured during days 25 to 29 only 
and so may not have been a reflection of the whole period of the study. Moreover, there is more variation 
for technical reasons in energy expenditure than in body weight and fat content and it is possible the 
analysis provided a false negative and it is indeed the energy expenditure that is the cause. 
Effect of genotype on the responses to THCV and rimonabant 
Because oral glucose tolerance is worse in GPR55 knockout mice, there may be a greater window of 
opportunity for THCV or rimonabant to improve metabolism in GPR55 knockout than wildtype mice. 
However, if the metabolic effects of THCV or rimonabant are partly mediated by GPR55, they might be 
less effective in GPR55 knockout than in wild-type mice. 
Nor could we detect any effect of genotype on insulin tolerance. This raises the possibility that GPR55 
regulates glucose-stimulated insulin secretion. A recent study found no difference between wildtype 
and GPR55 knockout mice murine isolated islets of Langerhans in their responses to rimonabant (Ruz-
Maldonado et al., 2020), which is consistent with our finding that genotype did not affect the effect of 
rimonabant on et al glucose homeostasis.  The authors did not discuss whether glucose-stimulated 
insulin secretion differed between islets from wild-type and knockout mice.   THCV and rimonabant had 
less effect in the knockout than the wild-type mice, suggesting, that both compounds  reduce body 
weight partly via GPR55. Based on the day-56 data, the effect of rimonabant on body weight gain was 
33% less in the knockout than the wild-type mice (P<0.001). The equivalent value for THCV was 19%, 
but these were not significantly different effects. Moreover, although the effect of genotype on the 
response to THCV on day 56 was not statistically significant, it was significant on a number of previous 
days and over all days. 
The effects of rimonabant and THCV on body fat content could not be accounted for by differences in 
energy expenditure. We cannot, however, exclude the possibility that the latter measurements were 
insufficiently powered to detect a statistically significant effect. By contrast with our findings, Bjursell et 
al. (Bjursell et al., 2016) found no effect of genotype on weight loss over 14 days in response to 
rimonabant in cafeteria-fed mice. They did not have an untreated group and they raise the possibility 
that the dose they used was too low, However, it was almost the same dose that we used and so we 
cannot explain this difference in our findings. 
Conclusions 
There are varied reports on the effect of deletion of GPR55 on energy balance and glucose homeostasis 
in mice. Our two experiments differ from others in finding impaired glucose tolerance in GPR55 
knockout mice in the absence of any effect on body weight, body composition, locomotor activity or 
energy expenditure. Nor could we detect any effect on insulin tolerance. The possibility that GPR55 
regulates glucose-stimulated insulin secretion merits further investigation. We also found that the 
reduction in weight gain elicited by THCV and rimonabant were in part mediated by GPR55. 
 
Acknowledgements 
We would like to thank GW Research Ltd for their support of the work. 
 
References 
Anavi-Goffer S, Baillie G, Irving AJ, Gertsch J, Greig IR, Pertwee RG, Ross RA. (2012). Modulation of 
L-α-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by 
cannabinoids. J Biol Chem. 287:91-104. 
Arch JR, Hislop D, Wang SJ, Speakman JR (2006). Some mathematical and technical issues in the 
measurement and interpretation of open-circuit indirect calorimetry in small animals. Int J Obes 30: 
1322-31. 
Arch JRS (2011). Thermogenesis and related metabolic targets in anti-diabetic therapy. Handb Exp 
Pharmacol. 203:201-55. 
Bjursell M, Ryberg E, Wu T, Greasley PJ, Bohlooly-Y M, Hjorth S. (2016). Deletion of Gpr55 Results in 
Subtle Effects on Energy Metabolism, Motor Activity and Thermal Pain Sensation. PLoS One. 
11:e0167965. 
Festing MF, Altman DG. (2002). Guidelines for the design and statistical analysis of experiments using 
laboratory animals. ILAR J. 43:244–58. 
Henstridge CM, Brown AJ, Waldhoer M (2016). GPR55: Metabolic Help or Hindrance? Trends 
Endocrinol Metab. 27:606-8. (2009).  
Henstridge CM, Balenga NA, Schröder R, Kargl JK, Platzer W, Martini L, Arthur S, Penman J, Whistler 
JL, Kostenis E, Waldhoer M, Irving AJ. (2010). GPR55 ligands promote receptor coupling to multiple 
signalling pathways. Br J Pharmacol.160:604-14. 
Kapur A, Zhao P, Sharir H, Bai Y, Caron MG, Barak LS, Abood ME. (2009). Atypical responsiveness of 
the orphan receptor GPR55 to cannabinoid ligands. J Biol Chem. 284:29817-27. 
Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, Mackie K. (2008) Proc Natl Acad Sci USA 105: 
2699–2704 
Lipina C, Rastedt W, Irving AJ, Hundal HS. (2012). New vistas for treatment of obesity and diabetes? 
Endocannabinoid signalling and metabolism in the modulation of energy balance. Bioessays. 34: 681-
91. 
Lipina C, Walsh SK, Mitchell SE, Speakman JR, Wainwright CL, Hundal HS. (2019). GPR55 deficiency 
is associated with increased adiposity and impaired insulin signaling in peripheral metabolic tissues. 
FASEB J. 33: 1299-1312. 
Liu B, Song S, Ruz-Maldonado I, Pingitore A, Huang GC, Baker D, Jones PM, Persaud SJ (2016). 
GPR55-dependent stimulation of insulin secretion from isolated mouse and human islets of 
Langerhans. Diabetes Obes Metab. 18: 1263-1273. 
Meadows A, Lee JH, Wu CS, Wei Q, Pradhan G, Yafi M, Lu HC, Sun Y (2016). Deletion of G-protein-
coupled receptor 55 promotes obesity by reducing physical activity. Int J Obes (Lond). 40:417-24. 
Moreno-Navarrete JM, Catalán V, Whyte L, Díaz-Arteaga A, Vázquez-Martínez R, Rotellar F, Guzmán 
R, Gómez-Ambrosi J, Pulido MR, Russell WR, Imbernón M, Ross RA, Malagón MM, Dieguez C, 
Fernández-Real JM, Frühbeck G, Nogueiras R. (2012). The L-α-lysophosphatidylinositol/GPR55 
system and its potential role in human obesity. Diabetes. 61:281-91. 
Pearce NJ, Arch JR, Clapham JC, Coghlan MP, Corcoran SL, Lister CA, Llano A, Moore GB, Murphy 
GJ, Smith SA, Taylor CM, Yates JW, Morrison AD, Harper AJ, Roxbee-Cox L, Abuin A, Wargent E, 
Holder JC. (2004). Development of glucose intolerance in male transgenic mice overexpressing human 
glycogen synthase kinase-3beta on a muscle-specific promoter. Metabolism. 53:1322-30. 
Pertwee RG (2007). GPR55: a new member of the cannabinoid receptor clan? Br J Pharmacol. 
152:984-6. 
Romero-Zerbo SY, Rafacho A, Díaz-Arteaga A, Suárez J, Quesada I, Imbernon M, Ross RA, Dieguez 
C, Rodríguez de Fonseca F, Nogueiras R, Nadal A, Bermúdez-Silva FJ. (2011). A role for the putative 
cannabinoid receptor GPR55 in the islets of Langerhans. J Endocrinol. 211:177-85. 
Ruz-Maldonado I, Liu B, Atanes P, Pingitore A, Huang GC, Choudhary P, Persaud SJ. (2020). The 
Cannabinoid Ligands SR141716A and AM251 Enhance Human and Mouse Islet Function via GPR55-
independent Signalling. Cell Mol Life Sci. doi: 10.1007/s00018-019-03433-6. Online ahead of print.  
Sharir H, Abood ME (2010). Pharmacological characterization of GPR55, a putative cannabinoid 
receptor. Pharmacol Ther. 126:301-13. 
Wang S, Cawthorne MA, Clapham JC. (2002). Enhanced diabetogenic effect of streptozotocin in mice 
overexpressing UCP-3 in skeletal muscle. Ann N Y Acad Sci 967:112-9. 
Wargent ET, O'Dowd JF, Zaibi MS, Gao D, Bing C, Trayhurn P, Cawthorne MA, Arch JR, Stocker CJ 
(2013). Contrasts between the effects of zinc-α2-glycoprotein, a putative β3/2-adrenoceptor agonist 
and the β3/2-adrenoceptor agonist BRL35135 in C57Bl/6 (ob/ob) mice. J Endocrinol. 216:157-68. 
Wargent ET, Zaibi MS, Silvestri C, Hislop DC, Stocker CJ, Stott CG, Guy GW, Duncan M, Di Marzo V, 
Cawthorne MA. (2013). The cannabinoid Δ(9)-tetrahydrocannabivarin (THCV) ameliorates insulin 
sensitivity in two mouse models of obesity. Nutr Diabetes. 3:e68 
Whyte LS, Ryberg E, Sims NA, Ridge SA, Mackie K, Greasley PJ, Ross RA, Rogers MJ. (2009). The 
putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc 
Natl Acad Sci U S A. 106:16511-6. 
 
Table and Figure Legends 
Table 1: Body composition, energy balance and locomotor activity in chow-fed mice in 
preliminary experiment. 
Food intake was measured daily when the mice were between 15 and 20 weeks of age, body 
composition and energy expenditure when they were 16 weeks old, and locomotor activity when they 
were 17 weeks old. Fat pad weights were measured at termination (20 weeks old). Energy expenditure 
was measured over 22 h beginning at 14:00 h. Locomotor activity was measured from 19:00 to 08:00 
h. Lights were out from 20:00 to 08:00 h. Where n = 6, measurements were recorded for pairs of mice 
and divided by two. Values of n were the same for wild-type and GPR55 knockout mice. Results are 
shown as the mean  SEM. Student’s t test returned no statistically significant differences between wild-
type and knockout mice. The lowest value of P was 0.08 for epididymal fat pad weights. Other values 
were > 0.25. 
Table 2: Body composition, energy balance and locomotor activity in high fat-fed mice in 
preliminary experiment. 
Food intake was measured daily when the mice were between 6 and 15 weeks of age, body composition 
by DEXA and NMR when they were 14 and 15 weeks old respectively, energy expenditure when they 
were 10 to 11 weeks old, and locomotor activity when they were 13 weeks old. Fat pad weights were 
measured at termination (15 weeks old). Energy expenditure was measured over 21 h beginning at 
14:00 h. Locomotor activity was measured from 19:00 to 08:00 h. Lights were out from 20:00 to 08:00 
h. Where n = 6 measurements were recorded for pairs of mice and divided by two, except for the 
knockout mice that was housed singly. Results are shown as the mean  SEM. There were no 
statistically significant differences between wild-type and knockout mice by Student’s t test. The lowest 
value of P was 0.053 for interscapular fat pad weights. Other values were > 0.1.   
Table 3: Fad pad weights and locomotor activity in the main experiment. 
Fat pad weights were measured at termination on day 56. Locomotor activity (n = 4) was measured for 
pairs of mice from 19:00 on day 43 to 08:00 h on day 44 when the mice were 22 weeks old and had 
been fed on the high fat diet for 16 weeks. Line break are given per mouse. Lights were out from 20:00 
to 08:00 h. The locomotor activity was not measured for the THCV-treated mice. Results are shown as 
the mean  SEM. Two-way ANOVA showed no significant effects of treatment or genotype on either fat 
pad weights or locomotor activity. 
Figure 1. Growth trajectory in GPR55 knockout and wild-type mice.. Bodyweight are shown for 
GPR55 knockout and control mice fed on chow (A), and high fat diet (B). Body weight change is shown 
for mice fed chow (C) or high fat diet (D). Results are shown as the mean  SEM. Two-way ANOVA 
showed no statistically significant differences between wild-type and knockout mice. 
Figure 2. Glucose and insulin tolerance in GPR55 knockout and wild-type mice fed on a standard 
chow diet. Blood glucose concentration (A) and plasma insulin (B) before and after a glucose load (t = 
0 min) at age 16 weeks after a 5 hour fast, and blood glucose concentration expressed as absolute 
values (C) or change from t = 0 min (D) following an insulin load (t = 0 min) at age 20 weeks after a 5 
hour fast. Results are shown as the mean  SEM. Two-way ANOVA showed no effect of genotype on 
blood glucose in the tolerance test. There was no statistically significant difference by two-way ANOVA 
in plasma insulin at t = -30 or t = +30 in the OGTT. Nor was there any difference between genotypes in 
blood glucose levels following an insulin load. 
Figure 3. Glucose and insulin tolerance in GPR55 knockout and wild-type mice fed on a high fat 
diet. Blood glucose concentration (A) and plasma insulin (B) before and after a glucose load (t = 0 min) 
at age 13 weeks after a 5 hour fast, and blood glucose concentration expressed as absolute values (C) 
or change from t = 0 min (D) following an insulin load (t = 0 min) at age 14 weeks after a 5 hour fast. 
Two-way ANOVA with time-matching followed by the FDR test showed that blood glucose was higher 
in the knockout mice at 30 and 60 min after dosing with glucose. Results are shown as the mean  
SEM. Two-way ANOVA followed by the FDR test showed plasma insulin was higher in the knockout 
mice 30 after glucose. Two-way ANOVA followed by the FDR test showed higher blood glucose levels 
in the knockouts 20 min to 60 min following an insulin load. There was no genotype effect on the change 
in blood glucose following an insulin load.  P<0.01. 
Figure 4. Bodyweight gain of GPR55 knockout and wild-type mice fed on a high fat diet and 
dosed with vehicle only (A), THCV (B) or rimonabant (C). Vehicle only values are shown in all panels 
to facilitate comparisons of the effects of genotypes and drugs. Results are shown as the mean  SEM. 
Two-way ANOVA followed by the FDR test showed an overall effect of genotype on body weight gain 
in response to both THCV (B) and rimonabant (C). 
Figure 5.  24-hour energy expenditure in mice fed on a high-fat diet and dosed with vehicle, 
THCV or rimonabant.. Energy expenditure measurements were performed on days 25-29 of dosing. 
Results are shown as the mean  SEM. Two-way ANOVA followed by the FDR test showed that 
expenditure elicited by. rimonabant significantly increased energy expenditure in wild-type mice. It did 
not increase energy expenditure significantly in knockout mice, but there was not a significant difference 
between energy expenditure in rimonabant-dosed wild-type mice and rimonabant-dosed knockout 
mice. P<0.01. 
Figure 6. Lean and fat mass of GPR55 knockout and wild-type mice fed on a high fat diet and 
dosed with vehicle, THCV or rimonabant. Body composition was measured by NMR on day 32. 
Results are shown as the mean  SEM. Two-way ANOVA followed by the FDR test showed no effect 
of either rimonabant or THCV on lean mass in either wild type or knockout mice (A). There was a 
significant effect of either THCV or rimonabant on fat mass in both wild-type and knockout mice (B). 
Genotype had no effect on the extent of fat mass reduction elicited by either THCV or rimonabant. 
P<0.05; P<0.01; P<0.0001. 
Figure 7. Glucose tolerance in GPR55 knockout and control mice on a high fat diet and treated 
with THCV or rimonabant.. Blood glucose concentrations during an oral glucose tolerance test on day 
21 are expressed as wild-type vs knockout mice (A), THCV and rimonabant-treated wild-type and 
knockout mice as absolute values (B and C) and relative to the respective control group in wild-type (D) 
and knockout mice (E). Results are shown as the mean  SEM. Two-way ANOVA followed by the FDR 
test showed that both THCV and rimonabant improved glucose tolerance in wildtype mice.  Neither 
THCV nor rimonabant had an overall significant effect on glucose tolerance in GPR55 knockout mice, 
although rimonabant lowered blood glucose 30 min after glucose load. No genotype differences were 
observed in the relative effects of either THCV or rimonabant. P<0.05; ††P<0.01; 
†††P<0.001 
Figure 8. Plasma insulin concentrations during a glucose tolerance in GPR55 knockout and wild-
type mice fed on a high fat diet and treated with vehicle, THCV or rimonabant. Plasma insulin 
concentrations in the oral glucose tolerance test on day 21. For clarity, the absolute values for the 
untreated mice are reproduced in panel A, and the significance in panel A is not repeated in panel C. 
Panels B and C only show significance relative to the relevant wild-type or knockout control mice. 
Knockout mice had significantly higher by two-way ANOVA plasma insulin levels 30 min following an 
(B [absolute values] and D [relative to control group]) and after (C [absolute values] and E [relative to 
control group]) a glucose load. Results are shown as the mean  SEM. Two-way ANOVA followed by 
the FDR test showed that both THCV- and rimonabant-dosed mice had lower plasma insulin 30 before 
and 30 after glucose. However, the relative effects of THCV and rimonabant were not significantly 
different between wild-type and knockout mice. P<0.05. 
Figure 9. Blood glucose concentrations during an insulin tolerance test in GPR55 knockout and 
wild-type mice fed on a high fat diet and treated with THCV or rimonabant. Results are shown as 
the mean  SEM. In an insulin tolerance test on day 38, two-way ANOVA followed by the FDR test 
showed  that blood glucose was lower in the THCV-treated wild-type mice before and after 
administration of insulin (A). There was a small non-significant overall effect of rimonabant (A). 
However, there was no overall effect of either drug on the fall in blood glucose after giving insulin to WT 
mice (C). The fall in blood glucose after giving insulin to the knockout mice reached statistical 
significance in the THCV-treated mice (Figures B, D) but there was no effect of genotype on the fall in 
blood glucose concentration in the control or the drug-treated mice (see Figure 8D for absolute values). 
†P<0.05; ††P<0.01; †††P<0.001 
Fig. 10. Blood glucose and plasma insulin concentrations in GPR55 knockout and wild-type mice 
fed on a high fat diet and treated with THCV or rimonabant. Results are shown as the mean  SEM. 
Two-way ANOVA followed by the FDR test showed no effect of genotype on blood glucose after a 5 h 
fast on days 8,15 and 56 (Figures A, B and C). On both days 8 and 15, blood glucose was lower in the 
THCV-treated and rimonabant-treated wild-type mice than in the control wild-type mice. Blood glucose 
was also lower in the rimonabant-treated knockout mice than in the control knockout mice. There was 
no effect of genotype on plasma insulin on days 8, 15 and 56 (Figures D, E and F). On days 8 and 15 
plasma insulin was lower in the THCV-treated and rimonabant-treated than in the control mice of the 
same genotype, although this only reached statistical significance in rimonabant-treated knockout mice 
on day 8 and rimonabant-treated wild-type mice on day 15. After 56 days of dosing both THCV and 
rimonabant reduced fasting plasma insulin in wild-type mice, but neither THCV nor rimonabant altered 
plasma insulin concentrations in GPR55 knockout mice (Figure F). The effects of THCV and rimonabant 
on plasma insulin were not significantly different in wild-type or GPR55 knockout mice at any time point 
(Figures G, H and I). P<0.05; P<0.01. 
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